Combination treatment for relapsed or refractory lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new combination of drugs for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The combination includes an experimental drug (EZH2i), an immunotherapy (glofitamab), and chemotherapy (GemOx), all given together to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have been diagnosed with diffuse large B-cell lymphoma (a fast-growing blood cancer).
- Your lymphoma has come back or not improved after at least one prior treatment that included rituximab.
- You have at least one tumor that can be measured on a scan or exam.
- You are generally able to care for yourself (ECOG score 0–2) and expected to live at least 3 more months.
- You have adequate organ and bone marrow function, and are not a candidate for a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
This study tests a new combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—in people with large B-cell lymphoma that has come back or not responded to earlier treatment. The goal is to see if this combination can shrink or control the lymphoma.
This trial tests two drugs, glofitamab and selinexor, for patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two previous treatments. The goal is to see if this combination can help control the cancer.
This trial tests a combination of medications for adults aged 60 and older with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The goal is to see if this treatment can help control the cancer and improve outcomes.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.